Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – What’s Next?

Genmab A/S (NASDAQ:GMAB) shares saw an uptick in trading volume on Monday . 3,133,669 shares were traded during trading, an increase of 259% from the previous session’s volume of 873,369 shares.The stock last traded at $22.40 and had previously closed at $24.14.

Analyst Ratings Changes

Several brokerages have recently issued reports on GMAB. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Truist Financial decreased their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Stock Performance

The firm has a market capitalization of $13.41 billion, a P/E ratio of 11.64, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The firm has a 50 day moving average price of $21.29 and a two-hundred day moving average price of $22.54.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently modified their holdings of the stock. Deep Track Capital LP bought a new stake in shares of Genmab A/S during the 4th quarter worth $41,740,000. Renaissance Technologies LLC boosted its stake in shares of Genmab A/S by 7.8% during the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company’s stock worth $40,199,000 after acquiring an additional 139,722 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Genmab A/S by 122.2% during the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company’s stock worth $35,612,000 after acquiring an additional 938,455 shares in the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company’s stock valued at $34,509,000 after purchasing an additional 1,038,400 shares in the last quarter. Finally, First Trust Advisors LP lifted its holdings in shares of Genmab A/S by 18.0% in the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company’s stock valued at $34,316,000 after purchasing an additional 251,241 shares in the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.